SER — Serina Therapeutics Share Price
0.000.00%
Last trade - 00:00- $58.10m
- $54.30m
- $0.06m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 90.65 | ||
| Price to Tang. Book | 90.65 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1,037.56 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -391.19% | ||
| Return on Equity | -364.68% | ||
| Operating Margin | -30442.86% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.36 | 0.14 | 0.03 | 0.14 | 0.06 | n/a | n/a | -49.63% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
Directors
- Gregory Bailey NEC
- Michael West CEO (67)
- Andrea Park CFO (49)
- Nafees Malik COO (43)
- Hal Sternberg VRD (67)
- Joanne Hackett IND (43)
- Annalisa Jenkins IND (55)
- Michael May IND (52)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 6th, 2017
- Public Since
- November 29th, 2018
- No. of Shareholders
- 100
- No. of Employees
- 12
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NYSE MKT
- Shares in Issue
- 9,932,215
- Address
- 601 Genome Way,, Suite 2001, HUNTSVILLE, 35806
- Web
- https://serinatherapeutics.com/
- Phone
- +1 2563279630
- Auditors
- Frazier & Deeter, LLC
Upcoming Events for SER
Q2 2025 Serina Therapeutics Inc Earnings Release
Similar to SER
Actinium Pharmaceuticals
NYSE MKT
Aeon Biopharma
NYSE MKT
Armata Pharmaceuticals
NYSE MKT
Azitra
NYSE MKT
Biomx
NYSE MKT
FAQ
What is the Serina Therapeutics share price?
As of Today at 23:10 UTC, shares in Serina Therapeutics are trading at $5.85. This share price information is delayed by 15 minutes.
How has the Serina Therapeutics share price performed this year?
Shares in Serina Therapeutics last closed at $5.85 and the price had moved by -36.35% over the past 365 days. In terms of relative price strength the Serina Therapeutics share price has underperformed the S&P500 Index by -41.25% over the past year.
What are the analyst and broker recommendations for Serina Therapeutics?
The overall consensus recommendation for Serina Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Serina Therapeutics dividend yield?
Serina Therapeutics does not currently pay a dividend.
Does Serina Therapeutics pay a dividend?
Serina Therapeutics does not currently pay a dividend.
When does Serina Therapeutics next pay dividends?
Serina Therapeutics does not currently pay a dividend.
How do I buy Serina Therapeutics shares?
To buy shares in Serina Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Serina Therapeutics?
As of the previous close price of $5.85, shares in Serina Therapeutics had a market capitalisation of $58.10m.
Where are Serina Therapeutics shares listed?
Here are the trading details for Serina Therapeutics:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: SER
What kind of share is Serina Therapeutics?
Based on an overall assessment of its quality, value and momentum Serina Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Serina Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Serina Therapeutics is $11.00. That is 88.03% above the last closing price of $5.85.
Analysts covering Serina Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.95 for the next financial year.
Find out moreWhat is the trend in the Serina Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Serina Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -10.34%.
As of the last closing price of $5.85, shares in Serina Therapeutics were trading -4.3% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Serina Therapeutics PE Ratio?
The Serina Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.85.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Serina Therapeutics?
Serina Therapeutics' management team is headed by:
- Gregory Bailey - NEC
- Michael West - CEO
- Andrea Park - CFO
- Nafees Malik - COO
- Hal Sternberg - VRD
- Joanne Hackett - IND
- Annalisa Jenkins - IND
- Michael May - IND